Background
Multiple system atrophy (MSA) is a rare, rapidly progressing and fatal neurodegenerative disease of unknown etiology that is clinically characterized by a variable combination of parkinsonism, cerebellar impairment, and autonomic and motor dysfunction [ 1 , 2 ]. Together with Parkinson disease (PD) and dementia with Lewy bodies (DLB), MSA belongs to the neurodegenerative group of α-synucleinopathies which are characterized by the deposition of aberrant α-synuclein (αS) in both glial cells and neurons. MSA is considered a synucleinopathy with specific glioneural degeneration involving striatonigral, olivopontocerebellar, autonomic, and peripheral nervous systems [ 3 , 4 ]. The neuropathological hallmark of this unique proteinopathy is the deposition of aberrant fibrillary αS in glial cells, mainly oligodendroglia, forming glial cytoplasmic inclusions (GCI) [ 5 ], which may even represent a primary pathologic event [ 3 , 6 , 7 ]. Less frequent are neuronal cytoplasmic inclusions (NCI) and other cellular deposits. Inclusion pathology is accompanied by neuronal loss, widespread demyelination, and gliosis. Degeneration of multiple neuronal pathways over the course of the disease causes a multifaceted clinical picture of this multisystem disorder [ 2 ]. The etiology and pathogenesis of MSA are not fully understood, but converging evidence suggests the propagation of misfolded αS from diseased neurons to oligodendroglia and its spreading from cell to cell in a “prion-like” manner [ 8 , 9 ], inducing oxidative stress (OS), proteosomal and mitochondrial dysfunction, dysregulation of myelin lipids, decreased neurotrophic factor activity, neuroinflammation, and energy failure that result in a multisystem involvement [ 3 , 4 , 10 – 12 ]. Recent experimental and human studies demonstrated that deposition of αS and other pathologic proteins induces neuroinflammation not only in MSA but also in other neurodegenerative diseases, e.g., PD and Alzheimer disease (AD) [ 13 – 24 ]. In MSA, αS has been shown to mediate formation of abnormal inclusion bodies and to induce neuroinflammation, which, interestingly, may also favor the formation of intracellular αS aggregates as a consequence of cytokine release and the shift to a pro-inflammatory environment [ 23 ]. αS may directly activate microglia, and recent studies have shown that only fibrillary αS is an important inducer of pro-inflammatory immune responses [ 25 ], associated with increased production of key pro-inflammatory cytokines, like tumor necrosis factor (TNF)-α and interleukin-1β (IL-1β) [ 26 ]. The association of activated microglial cells and GCI burden [ 27 ] suggests that pathologic αS triggers inflammatory response in α-synucleinopathies by affecting αS aggregation and provoking cell death [ 28 ]. This was corroborated by a number of experimental studies in vitro and in vivo [ 29 – 31 ]. These and other studies supported the notion that microglial activation may contribute to the progression of the neurodegenerative process in MSA and in other synucleinopathies via increased levels of reactive oxygen species (ROS) [ 20 , 32 , 33 ], like in other neurodegenerative diseases [ 31 ]. Although this mechanism is non-specific, it may be exploited for therapeutic and neuroprotective interventions.
TNFα in the central nervous system
TNFα, one of the key regulators in inflammation, belongs to the TNF ligand superfamily and is synthesized as a type II integral membrane protein occurring in a vast number of cell types. Within the central nervous system (CNS), microglia, astrocytes, and neurons are capable of synthesizing TNFα; however, activated microglia represent the main production site during neuroinflammatory processes [ 34 , 35 ]. Following translation, it is synthesized as a transmembrane protein (tmTNFα) and cleavage by TNFα-converting enzyme (TACE) releases soluble TNFα (sTNFα). Both forms exert their functions on two receptors, TNFα receptor (TNFR) type I and II, with sTNFα preferentially binding to TNFR I, whereas tmTNFα has higher affinity towards TNFR II [ 36 , 37 ]. The downstream signal-transduction cascades of TNFR I and TNFR II differ and imply the activation of numerous transcription factors including nuclear factor-kappa light chain enhancer of activated B cells (NF-κB) resulting in the regulation of various homeostatic and pathologic functions [ 38 , 39 ]. In neurons, depending on the eventually activated transcription factor down the signaling pathway, TNFα drives either pro-apoptotic or pro-survival cell fate via TNFR I or TNFR II, respectively. Excessive release of TNFα, especially in a chronic manner as can be seen in many neurodegenerative diseases, leads to a shift towards receptor-independent neuronal cell death, directly through the activation of caspase 8 and 10 and indirectly by mediating glutamate excitotoxicity independent of receptor subtype. However, TNFR II also seems to exhibit neuroprotective properties as TNFR II has been shown to be critical for maintaining the oligodendrocyte progenitor pool in a cuprizone model of demyelination [ 40 ]. Furthermore, there is upcoming evidence on the role of TNFR II in oligodendroglial differentiation and thus remyelination capacity [ 41 ]. In addition, after knock-out of TNFR II, hippocampal neurons reveal increased sensitivity towards TNFα toxicity, whereas loss of TNFR I did not have this effect [ 42 ]. This raises the question whether inhibition of TACE and thereby largely depleting TNFR I activation while preserving tmTNFα triggered TNFR II signaling is to be considered in MSA, which will be discussed later on.
TNFα in neurodegenerative disorders
Neuroinflammation characterized by microglial activation with secretion of many pro-inflammatory cytokines, in particular IL-1β and TNFα, has been implicated as main effector of the functional consequence of neurotoxicity, resulting in mitochondrial dysfunction [ 43 ], thereby contributing to the progress of neurodegeneration [ 13 , 17 , 44 – 47 ]. The two cytokines are potent mediators of microglial functions and modulate the complex networks of interactions of microglial-secreted molecules. The role of neuroinflammation has been demonstrated repeatedly in animal models of PD [ 21 , 29 , 48 , 49 ] and of MSA [ 49 – 51 ]. The major pro-inflammatory cytokine released by activated microglia is TNFα secreted by the brain resident microglia/macrophages in response to various stimuli. Microglial TNFα plays a major role in angiotensin-induced dopaminergic cell death. Microglial release of TNFα is mediated by activation of angiotensin type 1 receptors, NADPH (nicotinamide adenine dinucleotide phosphate)-oxidase, Rho-kinase, and NFK-β [ 52 ]. An early increase in TNF, which leads to protein thiol oxidation resulting in activation of ASK1 (apoptosis signal-regulating kinase 1)-p38 signaling, may be critical for neuroprotection in PD [ 53 ]. Increased levels of TNFα and IL-1β have been detected in the cerebrospinal fluid of PD patients [ 54 ]; in serum of patients with MSA [ 55 ]; in p t-mortem tissue of DLB, PD, and MSA [ 56 , 57 ]; and in animal models of PD [ 45 , 58 – 62 ]. It has been demonstrated to play a major role in neuroinflammation-related cell death in PD, AD, and other CNS disorders. Experimental studies indicated that TNFα is toxic for dopaminergic neurons in vivo [ 63 ] and in vitro [ 64 ]. Long-term expression of TNFα seems to be necessary to exert univocal toxic effects in the substantia nigra (SN) [ 65 ]. The increased frequency of TNF1031, a high producer allele of TNF, in Japanese MSA patients compared with controls [ 66 ] and increase of TNFα rs1799964 and IL-1β rs16944 polymorphisms in Chinese patients with MSA [ 67 ] suggest that they may represent genetic risk factors for MSA and that TNF may have a toxic effect in MSA. Interleukin-8, intercellular adhesion molecule-1, and TNFα polymorphisms significantly increased the risk of MSA [ 68 ].
The importance of TNFα in the processes of development of PD is strengthened by animal models of PD, where elevated levels of TNFα are seen in a manner consistent with that of clinical PD [ 59 , 61 , 62 ]. Agents that interfere with TNFα synthesis and release seem to be protective in experimental models of PD [ 69 , 70 ]. In other mouse models, conflicting findings regarding the protective effects of TNFα receptor deletion in toxin-induced PD have been reported [ 45 , 64 ]. However, if lower levels of TNFα were expressed in the SN, a transient neuroprotective effect against 6-hydroxydopamine toxicity was observed [ 71 ]. On the other hand, when the synthesis of TNFα is unregulatory overproduced, this results in inappropriate cell death. TNFα and NF-κB expression and microglial activation in MSA [ 72 ] indicate an important role of TNFα in oligodendroglial cell death in this disease. High expression of TNFα in degenerating regions suggests that this potent pro-inflammatory cytokine is a mediator of neuronal injury. Furthermore, markers of inflammation such as serum T-lymphocyte-associated cytokine concentrations give evidence of immune mechanisms contributing to PD and MSA disease progression [ 73 ]. The pathobiological effects of TNFα in neurodegeneration and, in particular, in PD have been critically reviewed recently [ 17 ]. Figure 1 illustrates the effects of chronic TNFα-mediated neuroinflammation on oligodendroglia and neurons: TNFα drives oligodendroglial and neuronal cell death via activation of pro-apoptotic pathways and by increasing αS misfolding and aggregation. Fig. 1 TNFα in MSA pathogenesis. Misfolded αS leads to microglial activation and subsequent microglial release of pro-inflammatory cytokines. High levels of TNFα in vulnerable brain areas in MSA contribute to αS aggregation and establish a pro-apoptotic environment in chronic disease
Due to the possible cyclic nature of αS aggregation/release and gliosis in MSA, interventions that target neuroinflammation may have the potency to slow the progression of the disease and increase the quality of life [ 23 ]. Recent studies have approached α-synucleinopathies including MSA, by use of immunotherapy [ 74 – 76 ]. They have been shown to reduce αS co-localization in oligodendrocytes and astrocytes but increased microglial uptake, with decreasing demyelination, neuronal death, and motor deficit [ 76 ]. Other studies aimed at microglia as therapeutic target, e.g., treatment of the PLP-αS mouse model with minocycline reduced the density of activated microglia and inducible nitric oxidase synthase and toll-like receptor 4 immunoreactivity [ 51 ]. Recently, an inducer of heat shock proteins (HSP), carbenoxalone, was shown to decrease pro-inflammatory cytokines and OS in a rotenone model of PD [ 77 ]. Other treatments targeting neuroinflammation in glia and immune cells may be promising therapeutic strategies for MSA [ 23 ].
TNFα inhibition as treatment strategy
Therapeutic regimes that interfere with either the synthesis of TNFα or the downregulation of TNFα/receptor interactions may have a considerable benefit to patients with such conditions. The use of agents similar to thalidomide and its analogs will inhibit TNFα protein biosynthesis, which will circumvent classical receptor subtype agonistic effects on signaling pathways. Furthermore, thalidomide will display biological activity in the CNS as it is a relatively small molecule and can cross the blood-brain barrier (BBB). Thus, it offers a better strategy for treating TNFα overproduction-induced disorders than that of currently available large proteins that bind and lower soluble TNFα [ 22 ]. Agents that interfere with pro-inflammatory events connected with TNFα synthesis and release have been shown to be protective in animal models of PD. Thalidomide has been shown to afford partial protection to striatal dopaminergic neurons in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model [ 69 , 70 ]. In transgenic mice, in which the gene for TNFα was functionally deleted, dopaminergic neurons in the striatum exhibited a greater degree of protection than wild-type littermates when challenged with MPTP [ 70 ]. However, in other mouse models employing gene targeting events on either one or both of the TNFα receptors (p55TNFR or p75TNFR), conflicting results regarding the protective effects of TNFα receptor deletion were reported [ 45 , 64 ].
Thalidomide is widely known for its deleterious side effects since the late 50s/early 60s when birth defects were observed after pregnant women were prescribed thalidomide to treat morning sickness [ 78 ]. In addition, neuropathies may occur [ 79 ]. Meanwhile, however, thalidomide has been re-evaluated for immunomodulatory purposes as it enhances TNFα mRNA destabilization and degradation and, thereby, lowers its rate of synthesis and secretion [ 80 , 81 ]. Furthermore, it is a co-stimulator of both CD8+ and CD4+ T cells [ 82 ], an inhibitor of angiogenesis [ 83 ] via its inhibitory actions on basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), and an inhibitor of the transcription factor NF-κB, whereas TNFα-induced leucine-rich α-2-glycoprotein-1 (LRG1) promotes angiogenesis and mesenchymal stem cell migration, this inhibition being a potential therapeutic approach [ 84 ].
Inhibition of the biological effects of sTNFα by etanercept and infliximab displayed beneficial properties against rheumatoid arthritis and other peripheral inflammatory diseases. Unfortunately, these agents are large macromolecules that minimally pass the BBB and thus will preclude their utility in CNS neurodegenerative disorders. BMS-561392 reduces the amount of sTNFα by inhibiting TACE; however, clinical phase II trials for rheumatoid arthritis have been halted due to mild hepatotoxicity [ 85 ], which might be due to the accumulation of tmTNFα and TNFRII increase. This effect has been described in available anti-TNF treatment, but in this case, hepatic injury usually takes a self-limiting course. In addition, BMS-561392 has shown poor ability to penetrate the BBB and can therefore not be considered a suitable candidate substrate. In contrast, thalidomide analogs can readily and rapidly pass through the BBB and, if well tolerated in animal studies, may be of potential in a wide spectrum of CNS diseases. The mechanisms underlying thalidomide’s actions have been summarized by [ 22 ]. In brief, the agent comprises two conjoined heterocyclic moieties—a phthalimide and a glutarimide ring showing structural modifications [ 86 – 89 ]. Recent studies confirmed that the actions of thiothalidomide agents were identical to that of thalidomide. They caused a concentration-dependent reduction in luciferase activity—consistent with the mechanism destabilizing the mRNA of TNFα [ 80 ], and thereby reduce TNFα synthesis. Thus, thalidomide and its analogs are excellent candidate agents for use in anti-TNFα therapies in a variety of diseases associated with neuroinflammation, particularly since they act at the levels of TNFα synthesis rather than for scavenge released protein or inhibit its interaction at a receptor level [ 22 ]. Infusion of mesenchymal stem cells in a transgenic mouse model of MSA inducing a downregulation of cytokines involved in neuroinflammation suggested a potent effect on immunomodulation and neuroprotection [ 90 ].
A recent study investigated the therapeutic efficacy of combining an unconventional anti-inflammatory therapy (lenalidomide, a small thalidomide derivative with immunomodulatory activity and therapeutic effects in multiple myeloma [ 91 – 93 ], with inhibition of TNFα production [ 93 , 94 ]) with an αS-reducing immunotherapeutic approach (CD5-D5 single chain antibody) in a novel transgenic mouse model of MSA pathogenesis. The combined treatment achieved better results than each method alone; it reduced astro- and microgliosis, αS levels, and partially improved deficits in MBP (myelin basic protein)-αS transgenic mice. These effects were associated with an activation of the Akt signaling pathway, which may mediate cytoprotective effects downstream TNFα [ 75 ]. Other recent studies demonstrated the neuroprotective and anti-inflammatory activities of allyl isothiocyanate (AITC), an aliphatic isothiocyanate derived from the precursor sinigrin present in vegetables of the Brassica family, on microglial cells through attenuation of JNK/NF-κB/TNFα signaling, which may have significance in neurodegeneration [ 95 ]. Combined active humoral and cellular immunization approaches, which are capable of triggering neuroprotective responses of regulatory T cells (Tregs), support the further development of multifunctional (vaccine) approaches for the treatment of synucleinopathies [ 96 ]. These results open the door for the design of more complex clinical trials in which a carefully planned combination of therapeutic approaches can complement each other to target multiple aspects of the pathobiology and pathogenesis of MSA and related neurodegenerative disorders.
Conclusions
TNFα-dependent neuroinflammation may play a key role in MSA pathogenesis, and its relevance has been underlined in various models of synucleinopathy. Targeting TNFα with readily available drugs may constitute a promising disease-modifying treatment in this hitherto incurable disease.
Abbreviations
Alzheimer disease
Blood-brain barrier
Dementia with Lewy bodies
Glial cytoplasmic inclusions
Heat shock proteins
Interleukin-1β
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Multiple system atrophy
Neuronal cytoplasmic inclusions
Nuclear factor-kappa light chain enhancer of activated B cells
Oxidative stress
Parkinson’s disease
Reactive oxygen species
Substantia nigra
Soluble TNFα
Tumor necrosis factor α-converting enzyme
Transmembrane tumor necrosis factor
TNFα receptor
Tumor necrosis factor α
α-Synuclein
Acknowledgements
Not applicable.
Funding
AN, GKW, KAJ, and TB received no funding and have no potential conflicts of interest that relate to the research covered in this review.
KAJ is funded by the Society for Support of Research in Experimental Neurology, Vienna, Austria.
GKW is employed by the Medical University of Innsbruck, Austria.
TB is employed by the Medical University of Vienna, Austria.
Availability of data and materials
Not applicable.
Authors’ contributions
AN, KAJ, and GKW wrote the primary draft. KAJ, TB, and GKW provided comments and proofread the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable as no patients/participants are involved in this review.
Competing interests
The authors declare that they have no competing interests.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
1. Fanciulli A Wenning GK Multiple-system atrophy N Engl J Med 2015 372 1375 1376 10.1056/NEJMra1311488 25830435
2. Krismer F Wenning GK Multiple system atrophy: insights into a rare and debilitating movement disorder Nat Rev Neurol 2017 13 232 243 10.1038/nrneurol.2017.26 28303913
3. Jellinger KA Wenning GK Multiple system atrophy: pathogenic mechanisms and biomarkers J Neural Transm (Vienna) 2016 123 555 572 10.1007/s00702-016-1545-2 27098666
4. Jellinger Kurt A. Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1 Journal of Alzheimer's Disease 2018 62 3 1141 1179 10.3233/JAD-170397 28984582 PMC5870010
5. Trojanowski JQ Revesz T MSA NWGo: proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy Neuropathol Appl Neurobiol 2007 33 615 620 10.1111/j.1365-2990.2007.00907.x 17990994
6. Bleasel JM Halliday GM Kim WS Animal modeling an oligodendrogliopathy--multiple system atrophy Acta Neuropathol Commun 2016 4 12 10.1186/s40478-016-0279-6 26860328 PMC4748629
7. Wenning GK Stefanova N Jellinger KA Poewe W Schlossmacher MG Multiple system atrophy: a primary oligodendrogliopathy Ann Neurol 2008 64 239 246 10.1002/ana.21465 18825660
8. Dehay B Vila M Bezard E Brundin P Kordower JH Alpha-synuclein propagation: new insights from animal models Mov Disord 2016 31 161 168 10.1002/mds.26370 26347034
9. Prusiner SB Woerman AL Mordes DA Watts JC Rampersaud R Berry DB Patel S Oehler A Lowe JK Kravitz SN Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism Proc Natl Acad Sci U S A 2015 112 E5308 E5317 10.1073/pnas.1514475112 26324905 PMC4586853
10. Jellinger KA Neuropathology and pathogenesis of multiple system atrophy: an update Curr Trends Neurol 2015 9 45 54
11. Jellinger KA Multiple system atrophy - a synucleinopathy with specific glioneuronal degeneration Austin J Clin Neurol 2015 2 1071
12. Ubhi K Low P Masliah E Multiple system atrophy: a clinical and neuropathological perspective Trends Neurosci 2011 34 581 590 10.1016/j.tins.2011.08.003 21962754 PMC3200496
13. Alam Q Alam MZ Mushtaq G Damanhouri GA Rasool M Kamal MA Haque A Inflammatory process in Alzheimer’s and Parkinson’s diseases: central role of cytokines Curr Pharm Des 2016 22 541 548 10.2174/1381612822666151125000300 26601965
14. Ahmed Z Asi YT Sailer A Lees AJ Houlden H Revesz T Holton JL The neuropathology, pathophysiology and genetics of multiple system atrophy Neuropathol Appl Neurobiol 2012 38 4 24 10.1111/j.1365-2990.2011.01234.x 22074330
15. Hirsch EC Hunot S Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 2009 8 382 397 10.1016/S1474-4422(09)70062-6 19296921
16. McGeer PL McGeer EG Glial reactions in Parkinson’s disease Mov Disord 2008 23 474 483 10.1002/mds.21751 18044695
17. Leal MC Casabona JC Puntel M Pitossi FJ Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease? Front Cell Neurosci 2013 7 53 10.3389/fncel.2013.00053 23641196 PMC3638129
18. Przedborski S Inflammation and Parkinson’s disease pathogenesis Mov Disord 2010 25 Suppl 1 S55 S57 10.1002/mds.22638 20187228
19. Mutoh T Current understanding of immunopathogenesis of Parkinson’s disease Austin J Clin Neurol 2016 3 3 1097
20. Sanchez-Guajardo V Tentillier N Romero-Ramos M The relation between α-synuclein and microglia in Parkinson’s disease: recent developments Neuroscience 2015 302 47 58 10.1016/j.neuroscience.2015.02.008 25684748
21. Teismann P Schulz JB Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation Cell Tissue Res 2004 318 149 161 10.1007/s00441-004-0944-0 15338271
22. Tweedie D Sambamurti K Greig NH TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets Curr Alzheimer Res 2007 4 378 385 10.2174/156720507781788873 17908040
23. Vieira BD Radford RA Chung RS Guillemin GJ Pountney DL Neuroinflammation in multiple system atrophy: response to and cause of α-synuclein aggregation Front Cell Neurosci 2015 9 437 10.3389/fncel.2015.00437 26778958 PMC4700780
24. Lee HJ Kim C Lee SJ Alpha-synuclein stimulation of astrocytes: potential role for neuroinflammation and neuroprotection Oxidative Med Cell Longev 2010 3 283 287 10.4161/oxim.3.4.12809 PMC2952089 20972375
25. Hoffmann A Ettle B Bruno A Kulinich A Hoffmann AC von Wittgenstein J Winkler J Xiang W Schlachetzki JC Alpha-synuclein activates BV2 microglia dependent on its aggregation state Biochem Biophys Res Commun 2016 479 881 886 10.1016/j.bbrc.2016.09.109 27666480
26. Boche D Perry VH Nicoll JA Review: activation patterns of microglia and their identification in the human brain Neuropathol Appl Neurobiol 2013 39 3 18 10.1111/nan.12011 23252647
27. Ishizawa K Komori T Sasaki S Arai N Mizutani T Hirose T Microglial activation parallels system degeneration in multiple system atrophy J Neuropathol Exp Neurol 2004 63 43 52 10.1093/jnen/63.1.43 14748560
28. Stefanova N Schanda K Klimaschewski L Poewe W Wenning GK Reindl M Tumor necrosis factor-alpha-induced cell death in U373 cells overexpressing alpha-synuclein J Neurosci Res 2003 73 334 340 10.1002/jnr.10662 12868067
29. Fellner L Jellinger KA Wenning GK Stefanova N Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts Acta Neuropathol 2011 121 675 693 10.1007/s00401-011-0833-z 21562886 PMC4730553
30. Stefanova N Fellner L Reindl M Masliah E Poewe W Wenning GK Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons Am J Pathol 2011 179 954 963 10.1016/j.ajpath.2011.04.013 21801874 PMC3157205
31. Fellner L Irschick R Schanda K Reindl M Klimaschewski L Poewe W Wenning GK Stefanova N Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia Glia 2013 61 349 360 10.1002/glia.22437 23108585 PMC3568908
32. Lim S Chun Y Lee JS Lee SJ Neuroinflammation in synucleinopathies Brain Pathol 2016 26 404 409 10.1111/bpa.12371 26940152 PMC8028946
33. Stefanova N Georgievska B Eriksson H Poewe W Wenning GK Myeloperoxidase inhibition ameliorates multiple system atrophy-like degeneration in a transgenic mouse model Neurotox Res 2012 21 393 404 10.1007/s12640-011-9294-3 22161470
34. Lieberman AP Pitha PM Shin HS Shin ML Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus Proc Natl Acad Sci U S A 1989 86 6348 6352 10.1073/pnas.86.16.6348 2474832 PMC297836
35. Perry VH Nicoll JA Holmes C Microglia in neurodegenerative disease Nat Rev Neurol 2010 6 193 201 10.1038/nrneurol.2010.17 20234358
36. Idriss HT Naismith JH TNF alpha and the TNF receptor superfamily: structure-function relationship(s) Microsc Res Tech 2000 50 184 195 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H 10891884
37. MacEwan DJ TNF receptor subtype signalling: differences and cellular consequences Cell Signal 2002 14 477 492 10.1016/S0898-6568(01)00262-5 11897488
38. Montgomery SL Bowers WJ Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system J NeuroImmune Pharmacol 2012 7 42 59 10.1007/s11481-011-9287-2 21728035
39. Santello M Volterra A TNFα in synaptic function: switching gears Trends Neurosci 2012 35 638 647 10.1016/j.tins.2012.06.001 22749718
40. Arnett HA Mason J Marino M Suzuki K Matsushima GK Ting JP TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination Nat Neurosci 2001 4 1116 1122 10.1038/nn738 11600888
41. Madsen PM Motti D Karmally S Szymkowski DE Lambertsen KL Bethea JR Brambilla R Oligodendroglial TNFR2 mediates membrane TNF-dependent repair in experimental autoimmune encephalomyelitis by promoting oligodendrocyte differentiation and remyelination J Neurosci 2016 36 5128 5143 10.1523/JNEUROSCI.0211-16.2016 27147664 PMC4854972
42. Yang L Lindholm K Konishi Y Li R Shen Y Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways J Neurosci 2002 22 3025 3032 10.1523/JNEUROSCI.22-08-03025.2002 11943805 PMC6757531
43. Russell AE, Doll DN, Sarkar SN, Simpkins JW. TNF-α and beyond: rapid mitochondrial dysfunction mediates TNF-α-induced neurotoxicity. J Clin Cell Immunol. 2016;7:467. 10.4172/2155-9899.1000467 PMC5482413 28652929
44. Liu B Hong JS Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention J Pharmacol Exp Ther 2003 304 1 7 10.1124/jpet.102.035048 12490568
45. Sriram K Matheson JM Benkovic SA Miller DB Luster MI O'Callaghan JP Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson’s disease FASEB J 2002 16 1474 1476 10.1096/fj.02-0216fje 12205053
46. Streit WJ Mrak RE Griffin WS Microglia and neuroinflammation: a pathological perspective J Neuroinflammation 2004 1 14 10.1186/1742-2094-1-14 15285801 PMC509427
47. Smith JA Das A Ray SK Banik NL Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases Brain Res Bull 2012 87 10 20 10.1016/j.brainresbull.2011.10.004 22024597 PMC9827422
48. Pott Godoy MC Tarelli R Ferrari CC Sarchi MI Pitossi FJ Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson’s disease Brain 2008 131 1880 1894 10.1093/brain/awn101 18504291 PMC2442423
49. Stefanova N Wenning GK Animal models of multiple system atrophy Clin Auton Res 2015 25 9 17 10.1007/s10286-014-0266-6 25585910 PMC4412689
50. Stefanova N Tison F Reindl M Poewe W Wenning GK Animal models of multiple system atrophy Trends Neurosci 2005 28 501 506 10.1016/j.tins.2005.07.002 16043239
51. Stefanova N Reindl M Neumann M Kahle PJ Poewe W Wenning GK Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy Mov Disord 2007 22 2196 2203 10.1002/mds.21671 17853477
52. Borrajo A Rodriguez-Perez AI Diaz-Ruiz C Guerra MJ Labandeira-Garcia JL Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin Glia 2014 62 145 157 10.1002/glia.22595 24272709
53. Ray A Sehgal N Karunakaran S Rangarajan G Ravindranath V MPTP activates ASK1-p38 MAPK signaling pathway through TNF-dependent Trx1 oxidation in parkinsonism mouse model Free Radic Biol Med 2015 87 312 325 10.1016/j.freeradbiomed.2015.06.041 26164633
54. Hunot S Dugas N Faucheux B Hartmann A Tardieu M Debré P Agid Y Dugas B Hirsch EC FcepsilonRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells J Neurosci 1999 19 3440 3447 10.1523/JNEUROSCI.19-09-03440.1999 10212304 PMC6782235
55. Kaufman E Hall S Surova Y Widner H Hansson O Lindqvist D Proinflammatory cytokines are elevated in serum of patients with multiple system atrophy PLoS One 2013 8 e62354 10.1371/journal.pone.0062354 23626805 PMC3633844
56. Croisier E Graeber MB Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration Acta Neuropathol 2006 112 517 530 10.1007/s00401-006-0119-z 16896905
57. Salvesen L Ullerup BH Sunay FB Brudek T Løkkegaard A Agander TK Winge K Pakkenberg B Changes in total cell numbers of the basal ganglia in patients with multiple system atrophy - a stereological study Neurobiol Dis 2015 74 104 113 10.1016/j.nbd.2014.11.008 25449905
58. Nagatsu T Sawada M Inflammatory process in Parkinson’s disease: role for cytokines Curr Pharm Des 2005 11 999 1016 10.2174/1381612053381620 15777250
59. Hébert G Arsaut J Dantzer R Demotes-Mainard J Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin Neurosci Lett 2003 349 191 195 10.1016/S0304-3940(03)00832-2 12951201
60. Ciesielska A Joniec I Przybyłkowski A Gromadzka G Kurkowska-Jastrzebska I Członkowska A Członkowski A Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson’s disease Acta Neurobiol Exp (Wars) 2003 63 117 126 12926538 10.55782/ane-2003-1461
61. Nagatsu T. Mogi M. Ichinose H. Togari A. Changes in cytokines and neurotrophins in Parkinson’s disease Advances in Research on Neurodegeneration 2000 Vienna Springer Vienna 277 290 10.1007/978-3-7091-6301-6_19 11205147
62. Mladenović A Perović M Raicević N Kanazir S Rakić L Ruzdijić S 6-Hydroxydopamine increases the level of TNFalpha and bax mRNA in the striatum and induces apoptosis of dopaminergic neurons in hemiparkinsonian rats Brain Res 2004 996 237 245 10.1016/j.brainres.2003.10.035 14697501
63. McGuire SO Ling ZD Lipton JW Sortwell CE Collier TJ Carvey PM Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons Exp Neurol 2001 169 219 230 10.1006/exnr.2001.7688 11358437
64. Leng A Mura A Feldon J Ferger B Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson’s disease Neurosci Lett 2005 375 107 111 10.1016/j.neulet.2004.10.077 15670651
65. Carvey PM Chen EY Lipton JW Tong CW Chang QA Ling ZD Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat J Neural Transm (Vienna) 2005 112 601 612 10.1007/s00702-004-0222-z 15583962
66. Nishimura M Kuno S Kaji R Kawakami H Influence of a tumor necrosis factor gene polymorphism in Japanese patients with multiple system atrophy Neurosci Lett 2005 374 218 221 10.1016/j.neulet.2004.10.056 15663966
67. Zhou Xin Wang Chunrong Chen Zhao Peng Yun Peng Huirong Hou Xuan Ye Wei Qiu Rong Xia Kun Tang Beisha Jiang Hong Association of TNF-α rs1799964 and IL-1β rs16944 polymorphisms with multiple system atrophy in Chinese Han population International Journal of Neuroscience 2018 128 8 761 764 10.1080/00207454.2017.1418346 29251119
68. Infante J Llorca J Berciano J Combarros O Interleukin-8, intercellular adhesion molecule-1 and tumour necrosis factor-alpha gene polymorphisms and the risk for multiple system atrophy J Neurol Sci 2005 228 11 13 10.1016/j.jns.2004.09.023 15607204
69. Boireau A Bordier F Dubédat P Pény C Impérato A Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice Neurosci Lett 1997 234 123 126 10.1016/S0304-3940(97)00685-X 9364513
70. Ferger B Leng A Mura A Hengerer B Feldon J Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum J Neurochem 2004 89 822 833 10.1111/j.1471-4159.2004.02399.x 15140182
71. Chertoff M Di Paolo N Schoeneberg A Depino A Ferrari C Wurst W Pfizenmaier K Eisel U Pitossi F Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice Exp Neurol 2011 227 237 251 10.1016/j.expneurol.2010.11.010 21093436
72. Probst-Cousin S Rickert CH Schmid KW Gullotta F Cell death mechanisms in multiple system atrophy J Neuropathol Exp Neurol 1998 57 814 821 10.1097/00005072-199809000-00002 9737544
73. Csencsits-Smith K Suescun J Li K Luo S Bick DL Schiess M Serum lymphocyte-associated cytokine concentrations change more rapidly over time in multiple system atrophy compared to Parkinson disease Neuroimmunomodulation 2016 23 301 308 10.1159/000460297 28395279 PMC5491391
74. Valera E Monzio Compagnoni G Masliah E Review: novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy Neuropathol Appl Neurobiol 2016 42 95 106 10.1111/nan.12312 26924723 PMC4785838
75. Valera E Spencer B Fields JA Trinh I Adame A Mante M Rockenstein E Desplats P Masliah E Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy Acta Neuropathol Commun 2017 5 2 10.1186/s40478-016-0409-1 28057080 PMC5217191
76. Mandler M Valera E Rockenstein E Mante M Weninger H Patrick C Adame A Schmidhuber S Santic R Schneeberger A Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy Mol Neurodegener 2015 10 10 10.1186/s13024-015-0008-9 25886309 PMC4411775
77. Thakur P Nehru B Inhibition of neuroinflammation and mitochondrial dysfunctions by carbenoxolone in the rotenone model of Parkinson’s disease Mol Neurobiol 2015 51 209 219 10.1007/s12035-014-8769-7 24946750
78. Taussig HB A study of the German outbreak of phocomelia. The thalidomide syndrome JAMA 1962 180 1106 1114 10.1001/jama.1962.03050260028005 13919869
79. Fullerton PM Kremer M Neuropathy after intake of thalidomide (distaval) Br Med J 1961 2 855 858 10.1136/bmj.2.5256.855 13702560 PMC1969856
80. Moreira AL Sampaio EP Zmuidzinas A Frindt P Smith KA Kaplan G Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation J Exp Med 1993 177 1675 1680 10.1084/jem.177.6.1675 8496685 PMC2191046
81. Niwayama S Turk BE Liu JO Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides J Med Chem 1996 39 3044 3045 10.1021/jm960284r 8759624
82. Marriott JB Clarke IA Dredge K Muller G Stirling D Dalgleish AG Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells Clin Exp Immunol 2002 130 75 84 10.1046/j.1365-2249.2002.01954.x 12296856 PMC1906488
83. D'Amato RJ Loughnan MS Flynn E Folkman J Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci U S A 1994 91 4082 4085 10.1073/pnas.91.9.4082 7513432 PMC43727
84. Wang Y Xu J Zhang X Wang C Huang Y Dai K TNF-α-induced LRG1 promotes angiogenesis and mesenchymal stem cell migration in the subchondral bone during osteoarthritis Cell Death Dis 2017 8 e2715 10.1038/cddis.2017.129 28358372 PMC5386532
85. Moss ML Sklair-Tavron L Nudelman R Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis Nat Clin Pract Rheumatol 2008 4 300 309 10.1038/ncprheum0797 18414459
86. Muller GW Corral LG Shire MG Wang H Moreira A Kaplan G Stirling DI Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity J Med Chem 1996 39 3238 3240 10.1021/jm9603328 8765505
87. Muller GW Chen R Huang SY Corral LG Wong LM Patterson RT Chen Y Kaplan G Stirling DI Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production Bioorg Med Chem Lett 1999 9 1625 1630 10.1016/S0960-894X(99)00250-4 10386948
88. Teubert U Zwingenberger K Wnendt S Eger K 5′-substituted thalidomide analogs as modulators of TNF-alpha Arch Pharm (Weinheim) 1998 331 7 12 10.1002/(SICI)1521-4184(199801)331:1<7::AID-ARDP7>3.0.CO;2-N 9507696
89. Hashimoto Y Structural development of biological response modifiers based on thalidomide Bioorg Med Chem 2002 10 461 479 10.1016/S0968-0896(01)00308-X 11814832
90. Stemberger S Jamnig A Stefanova N Lepperdinger G Reindl M Wenning GK Mesenchymal stem cells in a transgenic mouse model of multiple system atrophy: immunomodulation and neuroprotection PLoS One 2011 6 e19808 10.1371/journal.pone.0019808 21625635 PMC3097217
91. Martiniani R Di Loreto V Di Sano C Lombardo A Liberati AM Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma Adv Hematol 2012 2012 842945 10.1155/2012/842945 22919394 PMC3417169
92. Teo SK Properties of thalidomide and its analogues: implications for anticancer therapy AAPS J 2005 7 E14 E19 10.1208/aapsj070103 16146335 PMC2751493
93. Galustian C Meyer B Labarthe MC Dredge K Klaschka D Henry J Todryk S Chen R Muller G Stirling D The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Cancer Immunol Immunother 2009 58 1033 1045 10.1007/s00262-008-0620-4 19009291 PMC11030759
94. Zhu YX Kortuem KM Stewart AK Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma Leuk Lymphoma 2013 54 683 687 10.3109/10428194.2012.728597 22966948 PMC3931443
95. Subedi L, Venkatesan R, Kim SY. Neuroprotective and anti-inflammatory activities of allyl isothiocyanate through attenuation of JNK/NF-κB/TNF-α signaling. Int J Mol Sci. 2017;18:1423. 10.3390/ijms18071423 PMC5535914 28671636
96. Rockenstein E Ostroff G Dikengil F Rus F Mante M Florio J Adame A Trinh I Kim C Overk C Combined active humoral and cellular immunization approaches for the treatment of synucleinopathies J Neurosci 2018 38 1000 1014 10.1523/JNEUROSCI.1170-17.2017 29246926 PMC5783958